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Abstract: Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by 
the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy 
and the absence of an alternate diagnosis or exposure explaining these findings. There are cur-
rently no FDA-approved therapies available to treat this disease, and the 5-year   mortality is ∼80%. 
The pyridone derivative pirfenidone has been studied extensively as a possible   therapeutic 
agent for use in this deadly disease. This review will present the unique clinical features and 
management issues encountered by physicians caring for IPF patients, including the poor 
response to conventional therapy. The biochemistry and preclinical efficacy of pirfenidone will 
be discussed along with a comprehensive review of the clinical efficacy, safety, and side effects 
and   patient-centered foci such as quality of life and tolerability. It is hoped that this information 
will lend insight into the complex issues surrounding the use of pirfenidone in IPF and lead to 
further investigation of this agent as a possible therapy in this devastating disease.
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Introduction to management issues  
for idiopathic pulmonary fibrosis
In fibrosing diseases, regions of tissue that resemble scar tissue form in inappro-
priate locations such as the heart, lungs, and liver. There are at least 62 different 
fibrosing diseases, and collectively these are associated with ∼45% of deaths in the 
United States.1 The lung manifests multiple forms of fibrosis. Many of these diseases 
are associated with a secondary diagnosis such as underlying autoimmune disease or 
gastrointestinal reflux.2 Occupational exposures, such as asbestos and heavy metals, 
are another important cause of lung fibrosis. ‘Idiopathic pulmonary fibrosis’ (IPF) 
is defined as fibrosis in the setting of a high-resolution CT scan pattern and/or lung 
biopsy consistent with usual interstitial pneumonia (UIP) and lack of a known risk 
factor for interstitial lung disease.2 IPF affects ∼130,000 patients in the United States 
and has a 5-year mortality rate of 80%.3 This review will focus on the management 
aspects of this discrete clinicopathologic diagnosis and the potential use of pirfenidone 
in this patient population.
Importance of accurate diagnosis
Establishing an accurate diagnosis for the patient who presents with interstitial lung 
disease is an essential component of management.2 The initial workup of pulmonary 
fibrosis includes a complete history and physical examination. A detailed occupational 
history should be elicited along with detailed questions regarding gastrointestinal reflux Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and rheumatologic symptoms such as myopathic changes or 
Raynaud’s phenomenon. While recent American Thoracic 
Society (ATS) guidelines recommend against routine use of 
bronchoscopy in the diagnosis of IPF, serologic evaluation 
to uncover occult autoimmune disease remains an important 
aspect of the initial evaluation.2 High-resolution CT scan 
remains the cornerstone of diagnosis, with the pathognomic 
changes of UIP being peripheral, basilar predominance of 
fibrosis, honeycombing, and an absence of other findings such 
as a ground-glass appearance or nodules that might suggest 
an alternate diagnosis.2 Should the patient presentation be 
inconsistent with UIP/IPF, an alternate diagnosis may be 
sought with the use of open lung biopsy. Biopsy readings 
require the temporal heterogeneity of established fibrosis, 
fibroblastic foci, and normal-appearing lung parenchyma 
to be considered consistent with UIP.2 Findings of bron-
chocentricity, granulomas, and/or predominant inflammation 
are generally considered ‘inconsistent’ with UIP, and in 
this case, the patient should be diagnosed as ‘not UIP/IPF’. 
While revised diagnostic criteria were presented by Raghu 
et al at the 2010 meeting of the ATS, these recommenda-
tions have not yet been published and are not presented here. 
The decision to pursue biopsy should be considered in light 
of the potential for clinical decline following this invasive 
procedure since some studies suggest that open lung biopsy 
can lead to accelerated respiratory failure and even death.4 An 
especially helpful aspect of patient diagnosis is the use of 
multidisciplinary teams for the initial diagnosis of IPF. These 
teams include trained pulmonologists, pathologists, and 
radiologists and, in some cases, a rheumatologist.5
Pulmonary function testing
Once the diagnosis of UIP/IPF has been established, 
a number of patient care issues require ongoing attention. 
Patients are generally followed with serial measurements 
of forced vital capacity (FVC) and diffusion capacity of 
carbon monoxide (DLCO). Of these, the percent predicted 
FVC is most reflective of the degree of ventilatory impair-
ment as the DLCO can reflect vascular changes in addition 
to parenchymal   pathology.6 Six-minute walk tests (6MWTs) 
are also used but reflect overall patient conditioning rather 
than restrictive physiology. In addition, the clinical   utility 
of data obtained from this measure remains uncertain.7 
Total lung capacity (TLC) is used less frequently because 
of the relatively   preserved chest wall recoil and inspiratory 
muscle function.8 Reductions in FVC and DLCO are 
associated with poor survival,9,10 and longitudinal decline 
in these parameters portends an even worse prognosis.11 
Oxygen saturation (SpO2) is another important parameter of 
disease severity and is used to guide the decision to institute 
supplemental oxygen therapy.12
Management of gastrointestinal  
reflux disease
Effective management of the patient with IPF includes 
  attention to conditions that are commonly associated with 
this disease. For example, gastrointestinal reflux is   frequently 
found in IPF patients and may be a contributing factor to 
this disease.13,14 Intriguingly, a preliminary study with four 
IPF patients indicated that treatment of reflux can lead 
to stabilization of the FVC decline.15 Workup of GERD 
may include a barium swallow, endoscopy, and pH probe. 
  Management may range from simple lifestyle modifications 
to pharmacologic therapy with histamine receptor blockers 
or proton pump inhibitors. In some extreme cases, a   Nissen 
fundoplication may be warranted.16 Consultation with an 
esophageal specialist may be indicated for particularly 
  challenging cases.
Acute exacerbations
IPF demonstrates significant associations with other cardio-
pulmonary disorders including coronary artery disease,17,18 
pulmonary embolism,19 sleep apnea,20 and lung cancer.21 
In addition, patients with IPF suffer heightened manifesta-
tions of respiratory infections. Thus, these comorbidities 
should be considered when evaluating the IPF patient who 
manifests clinical worsening. However, it is now recognized 
that patients with IPF are at risk for ‘acute exacerbations’, 
a clinical syndrome defined as a new (,1 month) increase 
in oxygen requirement, new ground-glass findings on CT, 
and diffuse alveolar damage pattern on histopathology.22,23 
These exacerbations account for up to 50% of deaths in IPF 
and may affect previously stable patients.24 Management of 
acute exacerbations includes ruling out possible infection 
(bacterial and viral) and, if clinically indicated, evaluation 
for life-threatening conditions such as coronary artery   disease 
and pulmonary embolism.22 There exists no consensus 
regarding medical therapies in acute   exacerbations. One 
small retrospective study reported that high-dose corticos-
teroids followed by cyclosporine may be beneficial in this 
population,25 although this treatment approach has not been 
studied systematically. Another small study reported that 
long-term use of Coumadin prevented acute exacerbations 
in patients with IPF,26 which may relate to modulation of the 
recently reported profibrotic effects of coagulation factors, 
although the generalizability of these results (which were Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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primarily obtained from inpatients) to outpatients seen in the 
clinic remains uncertain. Given the high mortality associated 
with acute exacerbations, they are considered legitimate 
targets for prevention and therapy. A possible role for pir-
fenidone in reducing the incidence of acute exacerbations 
will be discussed in the following sections.
Lung transplantation
One particularly important aspect of management is 
early referral for lung transplantation. Because IPF may 
progress rapidly, early referral to a transplant center is a 
crucial aspect of management. Lung transplantation is the 
only therapy shown to increase survival in IPF.27 While it 
has been   suggested that the rate of patient decline should 
  trigger early referral for orthotopic lung transplantation,28 
the inability to predict which patients will develop an 
  accelerated worsening and respiratory failure mandates 
that transplant referral be considered early on in the clinical 
course regardless of   apparent stability.29 Compared with 
single lung   transplantation, bilateral lung transplantation may 
confer improved outcomes such as bronchiolitis obliterans 
syndrome-free survival and increased 1-year survival.30 
In addition, single lung transplantation in patients with 
  pulmonary hypertension may increase the risk of primary 
graft dysfunction.31
Pharmacologic therapy
The results of pharmacologic trials for IPF have been 
  disappointing. Interferon gamma, which had in subgroup 
analysis of prior studies shown possible benefit on reducing 
the FVC decline in patients with early stage disease32 and 
overall mortality,33 failed to demonstrate similar   benefits in a 
multicenter, placebo-controlled trial.34 Similarly, the endothelin 
antagonist bosentan demonstrated a trend toward improved 
symptoms and delayed time to death in a   randomized trial 
of IPF patients,35 but this benefit was not seen in a recently 
completed larger phase III trial.36   High-dose N-acetylcysteine 
showed a modest but significant effect on preservation of FVC 
when used in combination therapy with prednisone and azathio-
prine compared to those patients randomized to prednisone and 
azathioprine only.37 However, because prednisone and azathio-
prine are not routinely used in the treatment of IPF, the benefit 
of N-acetylcysteine as monotherapy is unknown. The ongoing 
National Institutes of Health (NIH)-sponsored PANTHER trial 
is examining this question. Etanercept, a recombinant receptor 
for tumor necrosis factor α (TNF-α) with neutralizing activity, 
was tested in a 48-week-long randomized controlled trial of 
88 IPF patients that compared 25 mg etanercept twice weekly 
with placebo. While there was no difference in the primary 
outcome measure of percent-predicted FVC, DLCO, or resting 
PaO2, post-hoc analysis revealed a trend toward reduced dis-
ease progression in the etanercept-treated cohort.38 This study 
(which many thought was well designed but underpowered)39 
may lead to larger trials examining the role of etanercept in 
IPF.36 The recent NIH-sponsored Sildenafil Trial of Exercise 
Performance in Idiopathic Pulmonary Fibrosis, which exam-
ined the effect of sildenafil on the six-minute walking test in 
IPF patients with advanced disease, concluded that there was 
no physiologic improvement in patients receiving sildenafil.40 
However, symptoms were greatly improved, which the authors 
felt would be of benefit to patients suffering from IPF. When 
viewed in combination, these results underscore the need for 
the development of novel therapies that are efficacious for use 
in IPF. For this reason, pirfenidone, which has shown promising 
results in preclinical studies, has been proposed for use in this 
difficult-to-treat population.
History of pirfenidone
Starting with the previous observation that some pyridones 
had analgesic properties, Gadekar investigated several 
pyridone derivatives and found that 5-methyl-1-phenyl-2-
(1H)-  pyridone (which was then later named pirfenidone) had 
analgesic, antipyretic, and antiinflammatory activities and 
lowered serum uric acid and serum glucose with low   toxicity.41 
Later, apparently starting with the hypothesis that some 
anti-inflammatory drugs might be useful for the treatment of 
fibrosis, Margolin found that pirfenidone could function as 
an orally available antifibrotic in rats.42 Oral pirfenidone was 
also found to be effective as an antifibrotic in the bleomycin-
induced hamster pulmonary fibrosis model.43
InterMune, Inc purchased the patent rights for pirfeni-
done for the United States and Europe from Marnac, Inc in 
2007. In Japan, pirfenidone is sold by Shionogi as Pirespa®. 
In October 2010, the Indian drug company Cipla began sales 
of generic pirfenidone (trade name Pirfenex) in India for the 
treatment of IPF.
Pirfenidone mode of action
Despite impressive advances, much remains to be under-
stood about the mechanism of action of pirfenidone. 
  Pirfenidone inhibits cell proliferation, apparently by 
  inhibiting DNA   synthesis, in human myometrial and leio-
myoma cells and also decreases levels of mRNAs encod-
ing collagen I and collagen III in these cells.44 In human 
retinal   pigment   epithelial cells, pirfenidone inhibits a 
transforming growth factor (TGF)-β1-induced increase in Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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fibronectin synthesis.45 In a patent application, Margolin 
found that pirfenidone inhibited, among other things, fibro-
blast growth factor–induced fibroblast proliferation and 
TGF-β1-induced collagen production from fibroblasts,46 
and in a hamster model, pirfenidone decreased collagen 
gene expression.47 Pirfenidone reduces prolyl hydroxylase 
activity in the lungs of hamsters treated with bleomycin, 
but has no effect on prolyl hydroxylase activity in vitro.47 
However, the structure of pirfenidone (Figure 1) resembles 
some prolyl hydroxylase inhibitors.48 Pirfenidone decreases 
levels of intercellular adhesion molecule-1 on fibroblasts.49 
In a hamster model of pulmonary fibrosis, pirfenidone 
decreased levels of platelet-derived growth factor.50 In a 
murine macrophage-like cell line, pirfenidone suppressed 
translation of the proinflammatory cytokine TNF-α,51 and 
in mice with lipopolysaccharide (LPS)-induced endotoxic 
shock, oral pirfenidone decreased plasma levels of the 
proinflammatory cytokines interferon-γ and interleukin-6 
and increased plasma levels of the antiinflammatory 
cytokine interleukin-10.51 In a murine bleomycin-induced 
pulmonary fibrosis model, pirfenidone increased the lung 
content of interferon-γ and decreased levels of monocyte 
chemoattractant protein-1, stromal cell-derived factor-1α, 
TGF-β1, basic fibroblast growth factor, interleukin-1β, 
interleukin-6, interleukin-12p40, and interleukin-18.52 In 
cell culture, pirfenidone inhibits T-cell activation and pro-
liferation.53 In vitro, pirfenidone scavenges hydroxyl radi-
cals.54 Taken together, the plethora of effects of pirfenidone 
point to its promise as having multiple beneficial effects on 
fibrosis. However, this multitude of effects also makes it 
difficult to determine its exact mechanism of action. Given 
the promise of pirfenidone, a considerable amount of work 
remains to be done to elucidate how it works, and this work 
should uncover additional targets that may be useful to 
develop next-generation antifibrotics.
Pirfenidone pharmacology  
and pharmacokinetics
In healthy human volunteers, orally administered   pirfenidone 
is absorbed within 20–60 min and cleared from the serum 
in 2–2.5 h, with food intake somewhat decreasing the 
  absorption.55 However, coadministration with food appears to 
improve tolerability in older adults.56 In humans,   pirfenidone 
is rapidly metabolized to primarily 5-carboxy pirfenidone 
(where the methyl group at the bottom of Figure 1 is 
  oxidized to a COOH group and to a lesser extent 5-hydroxy 
  pirfenidone, where the methyl group is replaced with an 
OH).56 These metabolites are then excreted in the urine. Since 
pirfenidone is rapidly metabolized, determining the effect 
of the metabolites on specific enzymatic activities, such as 
prolyl hydroxylase activity, needs to be determined.
Pirfenidone is effective  
in other disease models
Pirfenidone attenuated sclerosing peritonitis in a rat model57 
and was also effective in rat models of renal failure,58,59 hepatic 
fibrosis,60 and cardiac fibrosis.61 When human keloid tissues 
were implanted in nude mice, oral pirfenidone decreased 
the implant weights.62 Pirfenidone inhibited   LPS-induced 
toxic shock in a mouse model63 and was partially effective 
in decreasing ischemia/reperfusion-induced injury in a rat 
small intestine model.64 Finally, topical application of a 
10% pirfenidone solution three times a day for 7 days after 
thermoplasty-induced foreleg lameness in horses decreased 
swelling and heat and increased flexion.65 Together, these 
observations suggest that pirfenidone might be a useful 
therapeutic for several different diseases.
Efficacy studies
The initial human data supporting a role for pirfenidone in the 
treatment of IPF was published by Raghu et al in 1999.66 In 
this phase II study, 54 patients with severe IPF, many of whom 
were actively taking immunosuppressive medications such 
as prednisone, Imuran, or Cytoxan, were recruited from the 
University of Washington Interstitial Lung Disease Program 
and treated with open-label pirfenidone at a divided dose of 
3600 mg/day over a 25-month period. During this time, the 
1-year mortality was 22% and the 2-year   mortality was 37%. 
The authors compared these results to other published studies 
of IPF outcomes and found the comparison to be favorable. 
In terms of physiologic derangements, the authors found 
that over the study period, the trends for FVC and DLCO 
(for those patients able to perform them) remained stable. As 
the study progressed, fewer patients were able to complete 
N
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Figure  1  The  structure  of  pirfenidone.  After  ingestion,  the  CH3  group  at  the 
bottom of the structure is rapidly metabolized to primarily COOH and to a lesser 
extent OH.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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pulmonary function tests (PFTs) (at entry, all 54 patients 
performed this analysis, 6 months into the study, only 41 
patients were able to perform PFTs, and by 12 months, only 
31 patients performed PFTs). Thus, this stability in PFTs fails 
to reflect the clinical worsening experienced by a substantial 
number of patients, which the authors themselves pointed out. 
Another endpoint, cessation of immunosuppressive therapy, 
found that the majority of patients were able to discontinue 
prednisone or   azathioprine. Oxygen requirements appeared 
to remain stable after 12 months of therapy, and there was 
one patient who actually improved enough to completely 
discontinue supplemental oxygen. Side effects were relatively 
minor and will be   discussed in the following sections. While 
in retrospect, this study had many   shortcomings, including 
the small sample size recruited from only one medical center, 
the concomitant use of immunosuppression (which by today’s 
standards is not standard of care), and the lack of a control 
group; the results were encouraging enough to warrant further 
human investigation in both the United States and abroad.
In a study published in 2005, Azuma and colleagues 
e  xamined the efficacy of divided dose 1800 mg/day 
  pirfenidone in 107 Japanese patients with IPF who were 
recruited to take part in this randomized, placebo-controlled 
phase II   trial.67 This study randomized patients to pirfenidone 
or placebo at a 2:1 drug:placebo ratio. The primary endpoint 
was change in baseline on mean percent SpO2 on a   six-minute 
exercise test (6MET) that was personalized for each patient’s 
speed and comfort. Secondary endpoints included PFTs, 
HCRT patterns, frequency of acute exacerbations, and 
serum levels of KL-6, a marker of pneumocyte damage. 
I  nterestingly and somewhat unexpectedly, 25 patients were 
unable to perform the 6MET upon trial entry. Thus, the inves-
tigators opted to use this measurement only in the patients 
who could perform it on study entry.
The results for the primary endpoint of this study were 
negative in that for all comers, there was no difference in the 
lowest SpO2 of the 6MET between those patients receiving 
placebo or control. However, subgroup analysis revealed that 
of the patients who could complete the 6MET, pirfenidone 
demonstrated a significant increase in mean SpO2. Regarding 
secondary endpoints, the 6-month change in vital capacity 
(VC) between placebo and pirfenidone treated was negligible 
but by 9 months, the difference was greater and reached 
statistical significance (−0.13 L vs −0.01 L, P , 0.036). 
Changes in TLC, diffusion capacity, PaO2, HRCT severity, 
dyspnea, quality of life, and serum KL-6 were not affected 
by the administration of pirfenidone. However, despite this 
seeming lack of benefit, interim data analysis performed at 
the 9-month time point revealed a statistically significant 
reduction in acute exacerbations in the pirfenidone-treated 
group compared to control (14% vs 0%, P , 0.0003). 
This apparent benefit prompted the data safety monitoring 
board to discontinue the study early.
While some authors questioned the choice of   endpoints 
and the decision to end the trial early,68,69 the results 
of this second phase II trial were encouraging enough 
to prompt   several phase III trials. Taniguchi et al have 
recently   published the results of a multicenter, phase III 
  placebo-controlled trial performed in Japan.70 In this study, 
267 patients with IPF were randomized to receive 52 weeks 
of pirfenidone at high dose (1800 mg/day), low dose 
(1200 mg/day), or placebo. The   primary endpoint, which 
was changed before   unblinding, was change in VC between 
weeks 0 and 52. Secondary outcomes were progression-free 
survival (with progression defined as death or ,10% decline 
in VC) or inability to perform VC due to acute exacerba-
tion or symptoms. Tertiary endpoints included PFTs, acute 
exacerbation, biomarker measurements of alveolar damage 
such as surfactant-associated protein A, surfactant-associated 
protein D and KL-6 levels (a mucin-like glycoprotein), and 
symptoms. Demographics were largely similar between 
groups, although a nearly significant increase in smokers was 
detected in the 1800 mg/day group (P = 0.067).
Importantly, the primary endpoint was attained in 
that patients treated with 1800 mg/day of pirfenidone 
(when compared to placebo) demonstrated a significant 
attenuation of VC decline measured as both absolute   values 
(−0.09 L vs −0.16 L, P = 0.042) and percent predicted 
(−2.91 vs −5.13%, P = 0.044). Progression-free survival 
was also improved in the 1800 mg treated group (P = 0.028). 
Encouragingly, when compared to the placebo subjects, 
the 1200 mg/day group also displayed reduced VC decline 
(−0.08 L vs −0.16 L, P = 0.039). Neither the 1800 mg/day 
nor the 1200 mg/day recipients demonstrated improvements 
in the other measured endpoints. Based on these encourag-
ing results (which were not without some methodologic 
flaws71,72), pirfenidone was approved for monotherapy treat-
ment of IPF in Japan.
The results of two American Phase III trials were pre-
sented at the 2009 meeting of the ATS.36 The first of these, 
PIPF-004, was a phase III randomized, placebo-controlled, 
72-week trial that had three arms: high-dose pirfenidone 
(2403 mg/day), low-dose pirfenidone (1197 mg/day), and 
placebo. Enrollment proceeded in a 2:1:2 ratio and included 
a primary outcome of absolute change in percent-predicted 
FVC between enrollment and week 72. Secondary endpoints Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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included progression-free survival, worsened IPF, categorical 
change in percent predicted FVC, symptom measurements, 
percent-predicted DLCO, six-minute walk distance, and 
nadir SpO2. The exploratory endpoints assessed subjects for 
changes in quality of life, new oxygen requirement, all-cause 
mortality, and number of days without a hospitalization for 
respiratory reasons. When the data were unblinded, it was 
found that baseline characteristics of patients were similar 
throughout all three arms and that most patients (78% per 
group) finished the study. Importantly, a 157 mL (3.06%) 
reduction in percent-predicted FVC decline over the 72-week 
study period was noted in the patients receiving high-dose 
pirfenidone compared to control (P = 0.001). The   high-dose 
group also exhibited improvement in two secondary 
  endpoints: fewer patients experiencing a categorical decline 
in percent-predicted FVC and more patients demonstrat-
ing improved progression-free survival. The results of the 
  low-dose arm were reported to demonstrate a ‘dose response 
effect’, but the primary data are not available at this time.
In order to expand these promising results, InterMune 
undertook another 72-week phase III trial (PIPF006) com-
paring the effect of high-dose pirfenidone to placebo. This 
study randomized 344 patients in a 1:1 ratio and again used 
the primary endpoint of absolute change in percent-predicted 
FVC between weeks 0 and 72. The measured secondary 
endpoints assessed progression-free survival, worsened 
IPF, categorical change on percent-predicted FVC, dypsnea 
measurements, percent-predicted DLCO, distance achieved 
during 6MWT, and nadir SpO2. Exploratory outcomes were 
all-cause mortality, new oxygen requirement, number of days 
without a hospitalization for respiratory causes, and objective 
measures of quality of life.
Patients in this study were matched in terms of 
clinically relevant demographics and indices of severity. 
  Approximately 80% of patients completed treatment in both 
groups, with death or adverse events being the most com-
mon cause for dropout.36 Unfortunately, a beneficial effect 
primary endpoint of percent decline in percent-predicted 
FVC was not achieved (P = 0.501), although there was a 
significant treatment effect at weeks 12, 24, 36, and 48 of 
the study (P , 0.05 at these time points). Further analysis 
revealed that the effect of high-dose pirfenidone on percent-
predicted FVC decline at 72 weeks was similar to that seen 
in PIPF004, but that there was a more robust placebo effect 
in the PIPF006 study. The only secondary endpoint to be 
significant was the   distance attained in the 6MWT.
These findings were interpreted by the sponsor,  InterMune, 
as being clinically significant and prompted an application 
to the Food and Drug Administration (FDA) for approval 
of pirfenidone for the treatment of IPF. The   application 
was actually granted fast track approval, and the advisory 
panel recommended approval. Closer examination of the 
panel’s recommendation revealed that while 9/12 panel 
members recommended approval of pirfenidone, the efficacy 
vote was 7/12, indicating that fewer panel members thought 
that the drug was efficacious. Thus, it may not have surprised 
many observers when the FDA rejected the application in 
early May 2010. One concern was the perceived lack of 
efficacy and the lack of survival benefit (http://www.fda.
gov/  downloads/AdvisoryCommittees/CommitteesMeet 
ing   Materials/Drugs/Pulmonary-AllergyDrugsAdvisory 
  Committee/UCM208806.pdf). It is currently not clear 
whether future trials will be conducted.
Safety and tolerability
The safety profile of pirfenidone is excellent, and it appears 
to be generally well tolerated. The 1999 study by Raghu 
et al66 reported a high rate of adverse complaints related 
to pirfenidone (87%) though most of these were relatively 
minor as only 11% of subjects actually discontinued the drug. 
The most common effects were gastrointestinal upset (64%), 
fatigue (42%), and a plethora of dermatologic problems 
including photosensitivity (24%).66 In the 2005 Azuma study, 
which included a placebo arm, 98.5% of patients receiving 
pirfenidone reported any type of adverse symptoms compared 
to 88.9% in the placebo arm (P , 0.04).67 These included 
photosensitivity (43.8% vs 0%, P , 0.000), gastrointestinal 
upset (30.1% vs 8.3%, P , 0.01), nausea (21.9% vs 5.6%, 
P , 0.0314), anorexia (31.5% vs 5.6%, P , 0.0030), and 
fatigue (21.9% vs 2.8%, P , 0.0102). Despite this high rate 
of adverse events, only 15.1% of patients receiving pirfeni-
done discontinued the study drug versus 5.6% in the placebo 
arm. This difference did not meet statistical   significance 
(P = 0.2132).67 In the 2009 Taniguchi study, which utilized 
both high- and low-dose pirfenidone compared to   placebo, 
nearly all subjects experienced some adverse events (100% vs 
98.1% vs 99.1%, P values NS). Photosensitivity was sig-
nificantly more common in the pirfenidone-treated subjects 
regardless of dose (high dose 51.4% vs low dose 52.7% vs 
placebo 22.4%). Whereas anorexia was more pronounced in 
the high-dose group (16.5% vs 10.9% vs 2.8%), abdominal 
discomfort was more prevalent in the low-dose subjects (7.3% 
vs 2.8% high dose vs 0.0%). Dizziness and liver enzyme 
abnormalities were also seen with increased frequency in 
the high-dose group. Similar to earlier studies, these adverse 
events did not appear to prompt discontinuation of the drug Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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as withdrawal rates were similar in all three arms (18.3% vs 
20% vs 13.1%).70 The preliminary results of PIPF004 and 
PIPF006 both report increased adverse event-related study 
withdrawal in the high-dose group;36 however, because these 
results have not been published, the full data are not available 
for review at this time.
Patient-focused perspectives  
such as quality of life, patient  
satisfaction/acceptability,  
adherence, and uptake
There exist only limited data that evaluate pirfenidone’s 
effects on patient satisfaction and quality of life. While the 
1999 Raghu study did not examine quality of life as an end-
point, the four other studies (Azuma, Taniguchi, PIPF004, 
and PIPF006) did include symptoms and objective measures 
of quality of life. In all of these studies, the reported results do 
not demonstrate an improvement in quality of life measures. 
However, these data also indicate that pirfenidone does not 
negatively impact quality of life in patients with early or late 
stage IPF. In addition, the increase in side effects appears 
to have been tolerable for many patients, as despite the high 
rate of adverse events, the frequency of drug discontinuation 
was actually quite low. Thus, from these data, one can infer 
that pirfenidone is reasonably well tolerated.
Summary
Pirfenidone is an intriguing new drug for the treatment of 
IPF, with approval in Japan and further sales in India. A wide 
variety of effects on cells has made understanding the mode 
of action difficult, and further studies on the basic cell biol-
ogy and biochemistry of this drug will greatly expand our 
understanding of pulmonary fibrosis. Emerging data suggest 
that pirfenidone may be beneficial in mitigating FVC decline 
in patients with mild-to-moderate disease, and the side effects 
profile appears tolerable. It is thus hoped by many that future 
studies will demonstrate that pirfenidone represents a new 
era in the treatment of a currently fatal disease.
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